Are you Dr. Parasuraman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 25 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-8246Fax+1 617-730-0641- Is this information wrong?
Summary
- Dr. Sudha Parasuraman, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, New Hampshire, and California.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 1995 - 1998
University of Southern California/LAC+USC Medical CenterResidency, Pediatrics, 1994 - 1995
Children's Hospital of MichiganResidency, Pediatrics, 1992 - 1994
Kilpauk Medical CollegeClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2026
MA State Medical License 1998 - 2026
NH State Medical License 1998 - 2024
Clinical Trials
- Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme Start of enrollment: 2009 Jun 01
- A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome Start of enrollment: 2018 Jun 01
- Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01
Publications & Presentations
PubMed
- 19 citationsA phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.Toni K. Choueiri, Michael B. Atkins, Tracy L. Rose, Robert S. Alter, Yawen Ju, Katie Niland, Yan Wang, Robert Arbeit, Sudha Parasuraman, Lu Gan, David F. McDermott> ;Investigational New Drugs. 2021 Jan 28
- 56 citationsPreclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaLori S. Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R. Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu K...> ;Clinical Cancer Research. 2017 Apr 1
- 212 citationsA Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and LymphomasJeffrey R. Infante, P. A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Adam S. Crystal, ...> ;Clinical Cancer Research. 2016 Dec 1
- Join now to see all
Press Mentions
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-in-Class PARP7 InhibitorSeptember 4th, 2019
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business OfficerAugust 6th, 2019- X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of x4p-001-RD in Patients with WHIM SyndromeJune 15th, 2018
- Join now to see all
